Beam Therapeutics Secures $500 Million Non-Dilutive Financing for Risto-cel Launch

Key Facts

1Beam Therapeutics announced a $500 million strategic financing agreement with Sixth Street.

2$100 million was funded at close, with up to an additional $400 million available under the facility.

3The financing is non-dilutive with a 7-year term to support the launch of Risto-cel for sickle cell disease.

Beam Therapeutics Inc. (Nasdaq: BEAM) has announced a strategic financing agreement worth up to $500 million with investment firm Sixth Street. The arrangement provides $100 million in immediate funding at closing, with an additional $400 million available through the facility. This non-dilutive capital is structured with a seven-year term, specifically designed to support the commercial launch of Risto-cel, a treatment for sickle cell disease. By securing this funding, the company strengthens its balance sheet without diluting existing shareholder equity. The move extends Beam's cash runway during a critical phase as it prepares for the anticipated market entry of its lead therapeutic candidate.